Jardiance 25 mg 28 tab
Active Ingredient
Therapeutic Use of Jardiance 25 mg
Type 2 Diabetes Mellitus
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease.
Mechanism Of Action of Jardiance 25 mg
By inhibiting sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules, empagliflozin reduces reabsorption of filtered glucose from the tubular lumen and lowers the renal threshold for glucose (RTG). SGLT2 is the main site of filtered glucose reabsorption; reduction of filtered glucose reabsorption and lowering of RTG result in increased urinary excretion of glucose, thereby reducing plasma glucose concentrations.
Distribution
Vd: 73.8 L
Metabolism
Primarily through glucuronidation by UGT2B7, UGT1A3, UGT1A8, and UGT1A9 to minor metabolites
Excretion
Urine (54.4%; 50% as unchanged drug); feces (41.2%; majority as unchanged drug)
Drug Interactions
Loop Diuretics: Empagliflozin may enhance the hypotensive effect of Loop Diuretics. Monitor therapy
Maitake: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy
Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy
Nitisinone: May increase the serum concentration of OAT1/3 Substrates. Monitor therapy
Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy
Pretomanid: May increase the serum concentration of OAT1/3 Substrates. Monitor therapy
Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy
Adverse Effects
- Urinary tract infection (7.6-9.3%)
- Female genital mycotic infections (5.4-6.4%)
- Upper respiratory tract infection (3.1-4%)
- Increased urination (3.2-3.4%)
- Dyslipidemia (2.9-3.9%)
- Male genital mycotic infections (1.6-3.1%)
- Arthralgia (2.3-2.4%)
- Nausea (1.1-2.3%)
- Polydipsia (1.5-1.7%)
Read More:
Empagliflozin: Dosage, Mechanism/Onset of Action, Half-Life – Medicine.com
Ahmed (verified owner) –
Ok